Section 1 Short title
This Act may be cited as the “Treatment and Relief through Emerging and Accessible Therapy for PTSD TRICARE Act” or the “TREAT PTSD TRICARE Act”.
Treatment and Relief through Emerging and Accessible Therapy for PTSD TRICARE Act
A BILL
To direct the Secretary of Defense to furnish stellate ganglion block to members of the Armed Forces with post-traumatic stress disorder, and for other purposes.
Sec. 2 Provision of stellate ganglion block to members of the Armed Forces with post-traumatic stress disorder
Provision to members of the Armed Forces—
In general— Chapter 55 of title 10, United States Code, is amended by inserting after section 1074o the following new section:
“1074p. Provision of stellate ganglion block for certain members
“(a) In general—The Secretary shall furnish stellate ganglion block to any member of the Armed Forces (including the reserve components) who is performing or has performed active service and who—
“(1) is enrolled in the TRICARE program under chapter 55 of this title;
“(2) has been diagnosed with post-traumatic stress disorder; and
“(3) has elected to receive stellate ganglion block after being informed by a qualified health care provider of the risks and benefits of stellate ganglion block.
“(b) Provision of care—The Secretary may furnish stellate ganglion block under subsection (a) through a medical facility of the Department or through a qualified health care provider participating in a Department administered TRICARE health insurance program.”
Clerical amendment— The table of contents at the beginning of chapter 55 of title 10, United States Code, is amended by inserting after the item relating to section 1074o the following new item:
Update of joint clinical practice guideline—
Update of guideline— Not later than 180 days after the date of the enactment of this Act, the Secretary of Defense shall update the guideline titled the “VA/DOD Clinical Practice Guideline (CPG) for the Management of PTSD” (or such successor guideline) to ensure the guideline—
reflects the availability of stellate ganglion block as a therapy option; and
includes information on the clinical indicators and contraindicators for such therapy option.
Notification— Upon updating the guideline under paragraph (1), the Secretary shall notify the congressional defense committees (as such term is defined in section 101 of title 10, United States Code) of such update.
Effective date— The amendment made by subsection (a) shall take effect on the date that is 180 days after the date of the enactment of this Act.